GlassScriptPhysician profile
Joseph Durandis
NPI 1396038766
$5,840.33
in general payments reported to CMS, 2019-2025
28 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,362 · 2020: $676 · 2021: $1,122 · 2022: $583 · 2023: $380 · 2024: $387 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,248.28 | 2019-2025 | Dovato, Apretude |
| Janssen Pharmaceuticals, INC | $1,044.49 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $699.56 | 2019-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $480.65 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Sunovion Pharmaceuticals INC. | $305.53 | 2019-2022 | |
| Gilead Sciences, INC. | $298.99 | 2019-2025 | |
| Pfizer INC. | $258.98 | 2019-2025 | |
| Janssen Biotech, INC. | $224.49 | 2019 | |
| Lilly USA, LLC | $221.52 | 2020-2025 | Mounjaro, Zepbound |
| Galderma Laboratories, L.P. | $145.06 | 2019 | |
| Merck Sharp & Dohme LLC | $126.73 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.11 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $114.63 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $100.88 | 2019-2024 | Farxiga |
| Boston Scientific Corporation | $73.53 | 2023-2024 | Mylux Patient Kit With Mobile Device, Watchman Access System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $56.91 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $56.74 | 2020-2023 | |
| Abbott Laboratories | $37.77 | 2021-2024 | Freestyle Libre |
| Xeris Pharmaceuticals, INC. | $37.39 | 2022 | |
| Amgen INC. | $33.54 | 2024-2025 | Repatha, Repatha |
| Global Blood Therapeutics, INC. | $32.31 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $26.72 | 2023 | Rexulti |
| Allergan, INC. | $23.99 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.45 | 2021 | |
| Theratechnologies INC. | $16.05 | 2019 | |
| Emmaus Medical, INC. | $14.23 | 2019 | |
| Eisai INC. | $13.73 | 2021 | |
| Phadia US INC. | $12.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Durandis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.